Ανάλυση κόστους φαρμάκου και δαπανών υγείας
Analysis of drug development costs and health expenditures
View/
Keywords
Κόστος ; Φάρμακα ; Βελτιστοποίηση κόστους ; Αξιολόγηση κόστουςAbstract
The rising cost of drug development coupled with the increasing pressure on drug
pricing is fueling modern business models for the pharmaceutical industry. Publicprivate partnerships, adaptive plans and the use of big data offer opportunities for
greater efficiency in drug development. Only the future will show which of these
approaches will help most. At present, all are considered candidates to make research
and development of medicines more effective. Their best admixture is likely to be a
specific design question. However, these opportunities can only be exploited if the
inherent limitations of each of them are understood. For all of these areas, it can be
concluded that it is no longer the pharmaceutical industry alone that will develop new
drugs. On the contrary, it is suggested that the timely dialogue between
pharmaceutical companies, academic researchers, regulators, health technology
evaluators, payers and, in particular, patients, will increasingly shape the way new
drugs are developed for addressing existing medical needs. The present study studies
all the above elements related to the cost of a drug in order to evaluate it and to search
for ways to optimize it.
Postgraduate Studies Programme
Οικονομικά και Διοίκηση της ΥγείαςDepartment
Σχολή Οικονομικών, Επιχειρηματικών και Διεθνών Σπουδών. Τμήμα Οικονομικής ΕπιστήμηςNumber of pages
111Language
GreekCollections
Except where otherwise noted, this item's license is described as
Attribution-NonCommercial-NoDerivatives 4.0 Διεθνές
Attribution-NonCommercial-NoDerivatives 4.0 Διεθνές